Receptor activator of NF-κB ligand, macrophage inflammatory protein-1α, and the proteasome: Novel therapeutic targets in myeloma

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 813-817

  Oyajobi, Babatunde O ^a,b   Mundy, Gregory R ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

26S proteasome; MIP 1 ; Multiple myeloma; Osteolytic bone lesions; Osteoprotegerin; Proteasome inhibitors; PSI; RANK.Fc; RANKL

Indexed keywords

BORTEZOMIB; BORTEZONIB; CYTOKINE ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME; PROTEASOME INHIBITOR; PS 344; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE ATROPHY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; MOUSE; MYELOMA; NONHUMAN; OSTEOLYSIS; PARAPLEGIA; PLASMACYTOMA; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0037302195     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11133     Document Type: Conference Paper

References (42)

1. Mundy GR. Myeloma bone disease. Eur J Cancer. 1998;34: 246-251.
2. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795-823.
3. Oyajobi BO, Garrett IR, Williams PJ, et al. A soluble murine receptor activator of NF-κB-human immunoglobulin fusion protein (RANK.Fc) inhibits bone resorption in a murine model of human multiple myeloma bone disease. J Bone Miner Res. 2000;15(Suppl):S176a.
4. Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity. Blood. 2000;96:1953-1960.
5. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001;61:2572-2578.
6. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363-14367.
7. Mariani SM, Matib M, Armandola EA, Kramer PH. Interleukin-1α-converting enzyme related protease/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Exp Med. 1997;137:221-229.
8. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med. 1998;5:146-148.
9. Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood. 1999;93:1697-1706.
10. Garrett IR, Dallas S, Radl J, Mundy GR. A murine model of myeloma bone disease. Bone. 1997;20:515-520.
11. Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MM, de Leeuw AM. Animal model of human disease: multiple myeloma. Am J Pathol. 1988;132:593-597.
12. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J. 2000;1:351-356.
13. 1-VCAM-1 interaction. Bone. 1998;23(Suppl):S180a.
14. Cruz JC, Alsina M, Craig F, et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol. 2001; 29:441-447.
15. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA. 2001;98:11581-11586.
16. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98:3534-3540.
17. Vanderkerken K, Asosingh K, Van Camp B, Croucher PI. Anti-tumor effect of recombinant osteoprotegerin in the murine 5T33 model [abstract]. Blood. 2001;98(Suppl):637a.
18. Choi S, Cruz JC, Craig J, Anderson J, Roodman GD, Alsina M. Macrophage inflammatory protein (MID-1α is a potential osteoclast stimulatory factor in myeloma. Blood. 2000;96: 671-675.
19. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001;2:108-115.
20. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001;97: 3349-3353.
21. Kukita T, Nomiyama H, Ohmoto Y, et al. Macrophage inflammatory protein-1α; (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest. 1997;76:399-406.
22. Oyajobi B, Williams PJ, Pulkrabek D, Franchin G, Sherry B, Mundy GR. In vivo osteoclastogenic effects of the CC chemokine, macrophage inflammatory protein (MIP)-1α. Bone. 2001;27:S81.
23. Arendt BK, Miller AL, Arora T, Tschumper RC, Jelinek DF. Evidence for functional chemokine receptors on myeloma cells [abstract]. Blood. 1998;92(Suppl):100a.
24. Oyajobi B, Williams P, Story B, Franchin G, Sherry B, Mundy GR. Marked reduction in myeloma bone disease and tumor burden in vivo with antibodies to MIP-1α. J Bone Miner Metab. 2001;19(Suppl):42.
25. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001;108:1833-1841.
26. Proudfoot AEI, Power CA, Wells TNC. The strategy of blocking the chemokine system to combat disease. Immunol Rev. 2000;177:246-256.
27. Proudfoor AE. Chemokine receptors: multi-faceted therapeutic targets. Nat Rev Immunol. 2002;2:106-115.
28. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science. 1996;274:1652-1659.
29. Elliot PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol. 2001;116:637-646.
30. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
31. Adams J, Elliot PJ. New agents in cancer clinical trials. Oncogene. 2000;19:6687-6692.
32. LeBlanc R, Catley L, Hideshima T, Pien CS, Elliot PJ, Anderson KC. Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model [abstract]. Blood. 2001;98(Suppl):774a.
33. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
34. Richardson PG, Berenson J, Irwin D, et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract]. Blood. 2001; 98(Suppl):774a.
35. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
36. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappa B (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br J Haematol. 2001;115:279-286.
37. Feinman R, Dangurde P, Miller S, et al. Proteasome inhibitor PS-341 inhibits constitutive NF-κB activation and bypasses the anti-apoptotic Bcl-2 signal in human multiple myeloma cells [abstract]. Blood. 2001;98(Suppl):640a.
38. Mayo MW, Baldwin AS. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55-M62.
39. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-αB2. Nat Med. 1997;3:1285-1289.
40. Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanazawa S. NF-κB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett. 1997;410:297-300.
41. Ma MH, Parker KM, Manyak S, et al. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway [abstract]. Blood. 2001;98(Suppl):473a.
42. Oyajobi BO, Williams P, Gupta A, et al. Mechanisms by which proteasome inhibition reduces myeloma tumor burden in bone. J Bone Miner Res. 2002;17(Suppl):S184a.